IFM Therapeutics

Today we announced that @Novartis has exercised an option to acquire all outstanding capital stock of IFM Due, our subsidiary focused on developing novel STING antagonists to address a variety of serious inflammation-driven diseases.

With the progression of 4 novel programs to the clinic and the closing of 3 major deals, we’re so proud of how far we’ve come in fewer than 8 years: bit.ly/49dV4OI

With the acquisition of IFM Due by Novartis, we have achieved 3 deals comprising 4 programs that have advanced to the clinic. With only $58 million of invested capital, this work has resulted in $750 million in realized returns and ~$4 billion in potential future milestones.

The acquisition of IFM Due by Novartis marks our second major deal with Novartis. IFM Tre’s lead candidate, acquired in 2019, is now in multiple phase 2 trials. We’re excited about the potential impact of our work for patients who need new therapies for #inflammatory diseases.

At IFM we're developing drugs that precisely target components of the body's master regulator of subsequent immune activity—the #innateimmune system. Innate immune biology offers various clinical opportunities across a variety of therapeutic areas. Learn more:

Do you know what happens when an NLR protein becomes activated? Inhibiting these pattern recognition receptors may bring more effective treatment options for patients with #inflammatory diseases. Learn more: bit.ly/3rQdPEn #NLRP3 #NLRP1 #innateimmunity

#DYK IFM was founded in 2015? Since then, we've advanced 3 novel programs from start to the clinic that target the #innateimmune system and provide new treatment options. Read our story: bit.ly/3FI2ACJ

Results from a recent study in Nature indicate that #NLRP1, Casp1 and Casp6 represent rational therapeutic targets against cognitive impairment and inflammation in #AlzheimersDisease. Read more:

Mutations that activate the #cGAS/STING pathway can cause a variety of #autoimmune and inflammatory diseases. Within our IFM Due subsidiary, we're working to develop therapies for serious conditions driven by this pathway. Learn more:

Cheers to the New Year! 2021 has shown us the impact the global science community can make to change and save lives. We're hopeful that the #newyear will continue to bring new scientific discoveries and treatments—here's to 2022! #Happynewyear #NewYear #newyear2022

Wishing you much health and happiness this holiday season! #HappyHolidays

Activation of the #NLRP1 #inflammasome leads to the induction of inflammatory cytokines and drives both rare and common diseases. Discover how we're developing potential drug candidates that target inflammasomes to treat #autoinflammatory and #autoimmunediseases:

Rare diseases such as #AGS and multiple self-healing palmoplantar carcinoma are associated with activation of #innateimmune pathways. See how we're working to develop therapies that precisely target the innate immune system and treat rare and #autoinflammatory diseases:

We're excited to announce the extension of our R&D collaboration agreement between @NovartisScience and IFM Due, an IFM subsidiary company, to develop #immunotherapies that inhibit the #cGAS-STING pathway. Read more: #innateimmune

How are we making advancements in therapies that target the #innateimmune system? We bring together key academic thought leaders & advisors in this field, along with an exceptionally talented group of #pharmaceutical #scientists & execs. Explore the team: bit.ly/3wSdZNj

We're so grateful for our hardworking, dedicated team here at IFM and the ability to continue to enhance lives through science. From our IFM family to yours, #HappyThanksgiving! #thankful #Thanksgiving2021

New research finds that a subgroup of SLE patients fails to engage HIF-regulated metabolic and proteasomal pathways, causing the accumulation of mitochondria-containing red blood cells, eventually leading to #cGAS-STING-dependent #inflammation. Read more in our Science Spotlight:

#DYK Alzheimer's disease is the most common type of #dementia in the world? In a recent study, DNA damage in mice was increased in #AlzheimersDisease, and further, demonstrated that #cGAS–STING and NAD+ pathways are potential therapeutic targets: #AlzheimersDiseaseAwarenessMonth

Progress in understanding the #innateimmune system has allowed us to develop a leading portfolio of first-in-class small molecules that have the potential to treat patients with inflammation-driven diseases and #cancer. Explore more: bit.ly/3bCnEh8 #autoimmunedisease

Please help us welcome our new EVP, Head of Discovery to the IFM family! Stephanos Ioannidis has 18+ years’ experience in #oncology, #neuroscience and inflammation-focused drug development, and is an invaluable addition to our team! Excited to have you join us, Stephanos!